Stay updated on PDR001/MBG453 w/ Decitabine in AML Clinical Trial
Sign up to get notified when there's something new on the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page.

Latest updates to the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page adds a Locations section with listed sites (Massachusetts, Oregon, Texas, Victoria, Catalonia) and a revision tag v3.3.3, replacing the prior v3.3.2.SummaryDifference0.5%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe page now displays Revision: v3.3.2 as the current revision, replacing Revision: v3.2.0.SummaryDifference0.0%

- Check52 days agoChange DetectedThe government funding and operating status notice was removed from the page. The study details and eligibility criteria appear unchanged.SummaryDifference0.3%

- Check67 days agoChange DetectedStudy page content appears unchanged; the core sections such as Brief Summary, Detailed Description, Eligibility Criteria, Design, and Locations remain as published.SummaryDifference0.4%

- Check96 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check103 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to PDR001/MBG453 w/ Decitabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001/MBG453 w/ Decitabine in AML Clinical Trial page.